Ubs Group Ag Lava Therapeutics Nv Transaction History
Ubs Group Ag
- $528 Billion
- Q1 2025
A detailed history of Ubs Group Ag transactions in Lava Therapeutics Nv stock. As of the latest transaction made, Ubs Group Ag holds 16,895 shares of LVTX stock, worth $20,949. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,895
Previous 18,431
8.33%
Holding current value
$20,949
Previous $18,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding LVTX
# of Institutions
22Shares Held
4.93MCall Options Held
50.2KPut Options Held
200-
Redmile Group, LLC San Francisco, CA2.07MShares$2.57 Million0.28% of portfolio
-
Bml Capital Management, LLC Zionsville, IN1.96MShares$2.43 Million2.02% of portfolio
-
Bruce & Co., Inc. Chicago, IL522KShares$647,1230.28% of portfolio
-
Pathway Financial Advisors LLC103KShares$127,1000.03% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA65KShares$80,6000.0% of portfolio
About LAVA Therapeutics NV
- Ticker LVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,797,700
- Market Cap $32M
- Description
- LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer...